[Seite 125↓]

Literaturverzeichnis

1 Gimbrone MAJ, Leapman SB, Cotran RS, Folkman J (1972). Tumor dormancy in vivo by prevention of neovascularization. J Exp Med. 163, 261-276.

2 Folkman J, Shing Y (1992). Angiogenesis. J Biol Chem. 267: 10931-10934.

3 Brem S, Brem H, Folkman J, Finkelstein D, Patz A (1976) Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res. 36: 2807-2812.

4 Holmgren L, O´Reilly MS, Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med. 1: 149-15.

5 Ferrara N. Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells (1989). Biochem Biophys Res Commun. 161: 831-8.

6 Leung DW. Cachianes G. Kuang WJ. Goeddel DV. Ferrara N (1989). Vascular endothelial growth factor is a secreted mitogen. Science. 246: 1306-9.

7 Keck PJ. Hauser SD. Krivi G. Sanzo K. Warren T. Feder J. Connolly DT (1989).

8 Christofori G (1996). The role of fibroblast growth factor in tumor progression and angiogeenesis. In Tumor angiogenesis. R. Bicknell, CE Lewis and N Ferrara, eds (Oxford Press).

9 Folkman J, Shing Y (1992). Angiogenesis. J Biol Chem. 267: 10931-10934.

10 Friesel RE, Maciag T (1995). Molecular mechanisms of angiogenesis: fibroblast growth factor signal. FASEB J; 9: 919-925.

11 Risau W, Flamme I (1995). Vasculogenesis. Annu Rev Cell Dev Biol. 11: 73-91.

12 Senger DR, Galli SJ, Dvorak AM, Peruzzi CA, Harvey VS, Dvorak HF (183). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science; 219: 983-985.

13 Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, Orpana A, Pettersson RF, Alitalo K, Eriksson U (1996). Vascular Endothelial Growth Factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA; 93: 2476-2581.

14 Lee J, Gray A, Yuan J, Luoh SM, Abraham H, Wood WJ (1996). Vascular Endothelial Growth Factor- related protein: a ligand and specific activator of the tyrosine kinase receptor Flt-4. Proc Natl Acad Sci USA; 93: 1988-1992.


[Seite 126↓]

15 Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ (1995). Expression of vascular permeability factor (Vascular Endothelial Growth Factor) and its receptors in human breast cancer. Hum Path; 26: 86-91.

16 Hanahan D, Folkman J (1996). Patterns and Emerging Mechanisms of the Angiogenic Swith during Tumorigenesis. Cell; 86: 353-364.

17 Weidner N. Semple JP. Welch WR. Folkman J (1991). Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med. 324: 1-8.

18 Saclarides TJ. Speziale NJ. Drab E. Szeluga DJ. Rubin DB (1994). Tumor angiogenesis and rectal carcinoma. Dis Colon Rectum. 37: 921-926.

19 Machianini P. Fontanini G. Hardin JM. Squartini F. Angeletti FA (1992). Relation of neovascularization to metastasis of non-small cell lung cancer. Lancet. 340: 45-46.

20 Li VW. Folkert RD. Watanabe H. Yu C. Rupnik M. Barnes P. Scott RM. Black PM. Sallan SE, Folkman J (1994). Microvessel count and cerebrospinal fluid basic fibroblast grotwth factor in children with brain tumors. Lancet. 334: 82-86.

21 Weidner N. Carroll PR. Flax J. Blumenfeld W. and Folkman J (1993). Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 143: 401-409.

22 Millikan KW, Mall JW, Myers J, Hollinger EF, Doolas A, Saclarides TJ (2000). Do Angiogenesis and Growth Factor Expression predict Prognosis of Esophageal Cancer?". Am Surg. 66(4): 401-405; discussion 405-6.

23 Dameron KM, Volpert OV, Tainsky MA, Bouck NP (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science; 265: 1582-1584.

24 Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP (1990). A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA; 87: 6624-6628.

25 Metchnikoff E.. "Über die Immunität" . In C.R. 13éme Congrés Internationale de Medicine, 1900 Paris, Section bacteriologie et parasitologie: 11-27.

26 Engermann RL, Pfaffenbach D, Davis MD (1967). Cell turnover of capillaries. Lab Invest, 17: 738-743.

27 Hobson B Denekamp J (1984). Endothelial proliferation in tumors and normal tissues: continuous labelling studies. Br J Cancer; 49: 405-413.


[Seite 127↓]

28 Barinaga M (1997). From bench top to bedside. Science. Nov 7; 278(5340): 1036-9.

29 Vacca A, Ribatti D, Presta M, Minischetti M, et al (1999). Bone marrow neovascularization, plasma cell angiogenic potential and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood; 93: 3064-3073.

30 Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo JM (2001). Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesisinhibitor TNP-470. Cancer Res. Jul 15; 61(14): 5491-8.

31 Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999; 341(21): 1565-1571.

32 O´Reilly MS, Holmgren L, Shing Y, Chen C, et al. (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by Lewis lung carcinoma. Cell; 79: 315-328.

33 De Jong JS, van Diest PJ, van der Valk P, Baak JP (2001). Expression of growth factors, growth factor receptors and apoptosis related proteins in breast cancer: relation to apoptotic rate. Breast Cancer Res Treat. Apr; 66(3): 201-8.

34 Neal DE, Marsh C, Bennett MK, Abel PD, et al (1985). Epidermal growth factor receptors in human bladder cancer: Comparison of invasive and superficial tumors. Lancet; 1: 366-36.

35 Mendel DB, Laird AD, Smolich BD, Blake RA, et al (2000). Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des.Feb; 15(1): 29-41. Review.

36 Xu X, Shen J, Mall JW, Myers JA, et al (1999). In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: Mechanisms of action. Biochem Pharmacol; 58,9: 1405-1413.

37 Xu X, Williams JW, Bremer EG, Finnegan A, Chong AS F (1995). Inhibition of protein tyrosine kinase phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem; 270: 12398-12403.

38 Shawver LK, Schwartz DP, Mann E, Chen H, et al (1997). Inhibition of plateled derived growth factor mediated signal transduction and tumor growth by N-[4-(trifluormethyl)-phenyl]5-methylisoxazole-4-carboxamide. Clin Cancer Res; 3: 1167-1177.


[Seite 128↓]

39 Mall JW, Myers JA, Xiulong Xu, Saclarides TJ, AW Philipp, Pollmann C (2002). Leflunomid reduziert den Angiogenesescore und das Tumorwachstum subkutan implantierter Kolonkarzinomzellen im Mausmodell. Chirurg; 73: 716-720..

40 Vlassenko AG, Thiessen B, Beattie BJ, Malkin MG, Blasberg RG (2000). Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI. J Neurooncol; 46(3): 249-59.

41 Zwingenberger K, Wnendt S (1996). Immunomodulation by Thalidomide: Systematic Review of the Literature and of unpublished observations. J Inflamm, 46: 177-211.

42 Ericsson T, Björkman S, Roth B, Fyge A, Höglund P (1995). Stereospecific determination, chiral inversion in vitro and pharmacocinetics in humans of the enantiomers of thalidomide. Chirality, 7: 44-52.

43 Koransky W, Ullberg S (1964). Autoradiographic investigations of c-labelled thalidomide and gluthetimide in pregnant mice. Proc Soc Exp Biol Med, 116: 512-516.

44 Wiedemann HR (1961). Hinweis auf eine derzeitige Häufung hypo- und aplastischer Fehlbildung der Gliedmassen. Med Welt, 37: 1863.

45 Mc Bride WG (1961). Thalidomide and congenital abnormalities. Lancet, (16. 12.): 1358.

46 Mellin G, Katzenstein M (1962). The saga of thalidomide (concluded). NEJM; 267: 1238-1244.

47 Neubert R, Neubert D (1996). Peculiarities and possible mode of action of thalidomide. In: Kavlock RJ, Daston GP, eds. Drug Toxicity in Embryonic development (Handbook of Experimental Pharmacology) Vol. 124/II. Berlin: Springer Verlag,: 41-119.

48 Calabrese L, Fleischer AB (2000). Thalidomide: Current and potential applications. Am J Med; 108: 487-495.

49 Ochnisky S, Verroust J, Bastuji-Garin S, et al. (1994). Thalidomide neuropathy incidence and clinico-electrophysiological findings in 42 Patients. Arch Dermatol, 130(1): 66-9.

50 Thalidomide (Package Insert). Warren, NJ; Celgene Corporation., 1998. 49.

51 Stephens TD, Bunde CJW, Fillmore BJ (2000) Mechanism of action in thalidomide teratogenesis. Biochem Pharm 12: 1489-1499.

52 Paulitschke M, Mall JW, Büttemeyer R et al. (2002). Vascular PTFE grafts endothelialised under defined flow: from in-vitro data to clinical use. Int J Art Org; 25: 632-634.

53 Moreira AL, Sampaio EP, Zmudzinas A et al. ( 1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med; 177: 1675-80.


[Seite 129↓]

54 Rowland TL, Mc Hugh SM, Deighton J, et al. (1998) Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacol; 40: 11-20.

55 Tavares JL, Wangoo A, Dilworth P, et al. (1997). Thalidomide reduces tumour necrosis factor alpha production by human alveolar macrophages. Respir Med; 91(1): 31-9.

56 Moreira AL, Tsenova-Berkova L, Wang J et al. (1997) Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis. Tubercle Lung Dis;: 78 47-55.

57 Kaplan G, Moreira AL, (1993). Cytokine regulation of disease progression in leprosy and tuberculosis. Immunobiology; 191(4-5): 564-8.

58 Faure M, Thivolet J, Gaucherand M (1980). Inhibition of PMN leucocytes chemotaxis by thalidomide. Arch Dermatol Res; 269: 275-280.

59 Geitz H, Handt S, Zwingenberger K (1996). Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology; 131: 213-221.

60 Barnhill RL, Doll NJ, Millikan LE, et al (1984). Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear monocytes and lymphocytes. J Am Acad Dermatol; 11: 814-819.

61 Mc Hugh SM, Rifkin IR, Deighton J, Wilson AB, Lachmann PJ, Ewan PW, Lockwood CM (1995). The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol, 99: 160-167.

62 Moller DR, Wysocka M, Greenlee BM et al (1997) Inhibition of IL-12 production by thalidomide. J Immunol; 159: 5157-5161.

63 Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G (1991). Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med, 173: 699-703.

64 Moreira AL, Sampaio EP, Zmuidzinas A, et al (1993). Thalidomide exerts its inhibitora action on tumour necrosis factor alpha by enhancing mRNA degradation. J Exp Med; 177(6): 699-703.

65 Klausner JD, Freedman VH, Kaplan G (1996). Thalidomide as an anti- TNF-a-inhibitor: implications for clinical use. Clin Immunol Immunopathol; 81: 219-223.


[Seite 130↓]

66 Sampaio EP, Moreira AL, Sarno EN, et al (1992). Prolonged treatment with recombinant interferon ? induces erythemy nododsum leprosum in lepromatous leprosy patients J Exp Med; 175: 1729-1737:

67 Sarno EN, Grau GE, Vieira LMN, Nery JA (1991). Serum levels of TNF-a and interleukin-1ß during leprosy reactional states. Clin Exp Immunol; 84: 103-108.

68 Sampaio EP, Kaplan G, Miranda A et al (1993). The influence of thalidomide on clinical and immunological manifestations of erythema nodosum leprosum. J Infect Dis; 168: 408-414.

69 Jacobson JM, Greenspan JS, Spritzler J et al (1997). Thalidomide for the treatment of aphtous ulcers in patients with human immunodeficiency virus infection. NEJM; 336: 1487-1493.

70 Wolkenstein P, Latarjet J, Roujeau JC (1998). Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet; 352: 1586-1589.

71 Strieter RM, Kunkel SJ, Bone RC (1993) Role of tumor necrosisi factor - alpha in disease states and inflammation. Crit Care Med; 21: 447-463.

72 Davidsen SK, Summers JB (1995). Inhibitors of TNF- a synthesis. Exp Opin Ther Patents; 5: 1087-1100.

73 Dixon SC, Kruger EA, Bauer KS, Figg WD (1999). Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells. Cancer Chemother Pharmacol; 43 (Suppl): 78-84.

74 Nguyen M, Tran C, Barsky S, et al. (1997) Thalidomide and chemotherapy combination: preliminary results of preclinical and clinical studies. Int J Oncol.; 10: 965-969.

75 Wnendt S, Finkam M, Winter W, Raabe G, Ossig J, Zwingenberger K (1996). Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide analogues. Chirality; 8(5): 390-6.

76 Neubert R, (1996). Thalidomide. In Spencer PS, Schaumburg HS (eds): "Experimental and clinical Neurotoxicology ". 2nd ed. Oxford University Press.

77 Gardner-Medwin JM (1996). Thalidomide in autoimmune conditions. Exp Opin Invest Drugs, 5: 829-841.

78 Swartz GM, Fogler WF, Shah JH, Papathanassiu A, Madsen JW, Green SJ (1998). Partially reduced analog of thalidomide inhibits experimental metastases in a murine B16-BL6 melanoma model. Proc Am Assoc Cancer Res, 39: 46.


[Seite 131↓]

79 Nguyen M, Tran C, Barsky S, Sun JR, Mc Bride W, Pegram M, Pietras R, Love S, Glaspy J (1997). Thalidomide and chemotherapy combination: Preliminary results of preclinical and clinical studies. Int J Oncol, 10(5): 965-969.

80 Gutman M, Szold A, Ravid A, Lazauskas T, Merimsky O, Klausner JM (1996). Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo. Anticancer Res; 16(6B): 3673-3677.

81 Kotoh T, Dhar KD, Masunaga R et al. (1999). Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice. Surgery; 125: 536-44.

82 Minchington AI, Fryer KH, Wendt KR, et al. (1996). The effect of thalidomide on experimental tumors and metastases. Anti-Cancer Drugs; 7: 339-343.

83 Verheul HM, Panigraphy D, Yuan J, D´Amato RJ. (1999) Combination therapy with thalidomide and sulindac inhibits tumor growth in rabbits. Br J Cancer; 79: 114-118.

84 Singhal S, Mehta J, Eddlemon P, et al. (1998). Marked Anti-tumor-effect from anti-angiogenesis therapy with Thalidomide in high risk refractory multiple myeloma. Blood 92, 10 Suppl. 318a.

85 Barlogie B, Desikan R, Munshi N, Singhal S, et al. (1998). Single course D.T. PACE Anti-Angiochemotherapy effects CR in plasma cell leucemia and fulminant multiple myeloma. Blood 92, Suppl. 1: 273b.

86 Politi P, Reboredo G, Losso M, Vujacich G, et al. (1998). Phase I trial of thalidomide in AIDS-related Kaposi Sarcoma. ASCO 17: 41a.

87 Bower M, Howard M, Gracie F, Phillips R, Fife K (1997). A phase II study of thalidomide for Kaposi´s sarcoma: Activity and correlation with KSHV DNA load. J Acquir Immune Defic Syndr Hum Retrovirol, 14(4): 28-30.

88 Fine HA, Loeffler JS, Kyritsis A, Wen P, et al. (1997). A phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high grade gliomas. Proceedings of the Annual Meeting of the American Society of Clinical Oncology 16: A1372.

89 Zeldis JB, Williams BA, Thomas SD, Elsayed ME (1999). S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther; 21: 319-330.

90 Salven P, Ruotsolainen T, Mattson K, Joensuu H (1998). High pre-treatment serum levels of vascular endothelial growth factor (VEGF) is associated with poor outcome in small cell lung cancer. Int. J. Cancer; 17 ; 79(2): 144-146.


[Seite 132↓]

91 Takigawa N, Segawa Y, Fujimoto N, Hotta K, Eguchi K. (1998). Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. Anticancer Res; 18(2B): 1251-4.

92 Matsuyama W, Hashiguchi T, Mizoguchi A, et al. (2000). Serum levels of Vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest; 118 (4): 948-51.

93 German Cancer Society: Kurzgefasste Interdisziplinäre Leitlinien, 2000; B15: 218-234.

94 Manegold C, Bülzebruck H, Drings P, Vogt-Moykopf I (1989). Prognostische Faktoren beim kleinzelligen Bronchialkarzinom. Onkologie 12: 240-245.

95 Schalhorn A. in Empfehlungen zur Diagnostik, Therapie und Nachsorge bei Tumoren der Lunge und des Mediastinums. 3. Auflage. 1995. Schriftenreihe des Tumorzentrum München.

96 Livingston RB (1980). Small cell carcinoma of the lung. Blood 56: 575-584.

97 Livingston RB (1988). Treatment of the advanced non-small-cell-carcinoma of the lung: The Southwest oncology Group experience. Sem Onco 15, Suppl; 7: 37-41.

98 Seeber S, Niederle N (1983). Chemotherapie des kleinzelligen Bronchialkarzinoms. In Hellriegel KP, Sack H (Hrsg): Bronchialkarzinom, Mammakarzinom, pp 11-18. Springer , Heidelberg New York.

99 Kelly K (2000). New chemotherapeutic agents for small cell lung cancer. Chest; 117(Suppl. 4): 156S-162S.

100 Roth BJ, Johnson DH, Einhorn LH, et al. (1992). Randomized study of cyclophosphamide, doxorubicin, vincristin versus cisplatin etoposide versus alternation of these regimens in small cell lung cancer: a phase III trial of the Southeastern cancer study group. J Clin Oncol; 10: 282-291.

101 Watine J (1999). Laboratory variables as additional staging parameters in patients with small cell lung carcinom. A systematic Review. Clin. Chem. Lab. Med.; 37(10): 931-938.

102 Keller T, Bitterlich N, Hilfenhaus S, Bigl H, Loser T, Leonhardt P (1998). Tumour markers in the diagnosis of bronchial carcinoma: new options using fuzzy logic-based tumour marker profiles. J. Cancer Res. Clin Oncol; 124(10): 565-574.

103 Beinert T, Binder D, Oehm C et al. (2000). Further evidence for oxidant-induced vascular endothelial growth factor up-regulation in the bronchoalveolar lavage fluid of lung cancer patients undergoing radio-chemotherapy. J. Cancer Res. Clin. Oncol. Jun; 126(6): 352-356.

104 De Jong JS, van Diest PJ, van der Valk P. Expression of growth factors, growth factor inhibitors and their receptors in invasive breast cancer. J. Pathol. 1998; 184(1): 53-7.


[Seite 133↓]

105 Brown LF, Berse B, Jackman RW (1995). Expression of vascular permeability factor (Vascular endothelial growth factor) and its receptors in breast cancer. Human Pathol.; 26: 86-91.

106 Nielsen HJ, Werther K, Mynster T, Svendsen MN, Rosendahl S et al.. Bacteria-induced release of white cell- and platelet-derived-vascular endothelial growth factor in vitro. Vox Sang, 2001; 80(3): 170-8.

107 Banks RE, forbes MA, Kinsey SE et al.. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br. J. Cancer, 1998; 78: 956-964.

108 Möhle R, Green D, Moore MAS, Machman RL et al.. Constitutive production and thrombin-release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc. Natl. Acad. Sci. USA, 1997; 94: 663-668.

109 Wolf M. Havemann K. (1995): Kleinzelliges Bronchialkarzinom. In: Seeber S. Schütte J. (Hrsg) Therapiekonzepte Onkologie. Springer Verlag, Berlin Heidelberg New York Tokio. S. 421-427.

110 Thiele K.-P. (1997). Prognostische Faktoren und Therapiestrategien beim kleinzelligen Bronchialkarzinom. In: Klinische Onkologie `97. Praxis. Verlag Hans Huber Bern. S.154a-h.

111 Jett JR, Everson L, Thernau TM, et al. (1990). Treatment of limited stage small-cell lung cancer with Cyclophosphamide, Doxorubicin and Vincristine with or without Etoposide: A randomised trial of the North Central Cancer Treatment Group. J Clin Oncol. 8: 33-38.

112 Mc Cracken JD, Janaki LM, Crowley JJ et al (1990). Concurrent Chemotherapy/Radiochemotherapy for limited small-cell disease Carcinoma: A Southwest Oncology Group Study. J of Clin Oncol. 8: 892-898.

113 Spiegelmann D, Maurer H, Ware JH, Perry MC, Chaniian AP, Comis R, Waton W, Zimmer B, Green M (1989). Prognostic factors in small cell lung cancer of the lung: an analysis of 1521 patients. J Clin Oncol. 7: 344-354.

114 Wolf M. Havemann K. Holle R. et al (1987). Cisplatin-Etoposide versus Ifosfamide-Etoposide combination chemotherapy in small cell lung cancer: A Multicenter German Randomized Trial. J Clin Oncol 5: 1880-1889.

115 Manegold C, Bülzebruck H, Drings P, Vogt-Moykopf I (1989). Prognostische Faktoren beim kleinzelligen Bronchialkarzinom. Onkologie 12: 240-245.


[Seite 134↓]

116 Schalhorn A. in Empfehlungen zur Diagnostik, Therapie und Nachsorge bei Tumoren der Lunge und des Mediastinums. 3. Auflage. 1995. Schriftenreihe des Tumorzentrum München.

117 Livingston RB (1980). Small cell carcinoma of the lung. Blood 56: 575-584.

118 Livingston RB (1988). Treatment of the advanced non-small-cell-carcinoma of the lung: The Southwest oncology Group experience. Sem Oncol1 5, Suppl; 7: 37-41.

119 Seeber S, Niederle N (1983). Chemotherapie des kleinzelligen Bronchialkarzinoms. In Hellriegel KP, Sack H (Hrsg): Bronchialkarzinom, Mammakarzinom, pp 11-18. Springer , Heidelberg New York.

120 Lassen U, Osterlind K, Hansen M, Dombernowsky P, Bergman B, Hansen HH. Long-term survival in small-cell lung cancer: Posttreatment characteristics in patients surviving 5 to 18+ years - an analysis of 1714 consecutive patients. J Clin Oncol 1995; 13 1215-1220.

121 Jensen PB, Sehested M, Langer SW, Hansen HH. Twenty-five years of chemotherapy in small cell lung cancer sends us back to the laboratory. Cancer Trea Rev 1999; 25: 377-386.

122 Postmus PE, Schramel FM, Smit EF. Evaluation of new drugs in small cell lung cancer: the activity of gemcitabine. Semin Oncol 1998; 25: 79-82.

123 Osterlind K: Chemotherapy in small cell lung cancer. Lung Cancer; European Respiratory Monograph 2001; Vol. 6: 234-258.

124 Ericsson T, Björkman S, Roth B, Fyge A, Höglund P (1995). Stereospecific determination, chiral inversion in vitro and pharmacocinetics in humans of the enantiomers of thalidomide. Chirality, 7: 44- 52.

125 Galligioni E, Ferro A (2001). Angiogenesis and antiangiogenic agents in non-small cell lung cancer. Lung Cancer; 34: 3-7.

126 Wong MP, Chan SY, Fu KH et al (2000). The angiopoietins tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lungs to non-small cell lung carcinomas. Lung Cancer; 29: 11-22.

127 Yamashita J, Ogawa M, Abe M, Nishida M (1999). Plateled derived growth factor/ thymidine phosphorylase concentrations differ in small cell and non-small cell lung cancer. Chest; 116 (1): 206-211.

128 Vesela D, Jelinek R (1994). Embryotoxicity in chick embryo of thalidomide hydrolysis products following metabolic activation by rat liver homogenate. Funct Dev Morphol; 4: 313-316.

129 Bauer KS, Dixon SC, Figg WD (1998). Inhibition of angiogenesis by thalidomide requires


[Seite 135↓]

metabolic activation, which is species -dependent.

130 D´Amato RJ, Loughnan MS, Flynn E, Folkman J (1994). Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci; 91: 4082-4085.

131 Stephens TD, Fillmore BJ (2000). Hypothesis: Thalidomide embryopathy - Proposed mechanism of action. Teratology; 61: 189-195.

132 Moreira AL, Friedlander DR, Shif B, Kaplan G, Zagzag D (1999). Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation. J Neurooncol; 43: 109-114.

133 Miller JM, Ginsberg M, McElfatick GC, Shonberg IL (1960). The anti-inflammatory effect and the analgetic property of thalidomide-268. Antibiot Med Clin Ther. 7: 743-746.

134 Nogueira AC, Gräfe M, Neubert R (1995). Effect of thalidomide and some derivates on the adhesion of lymphocytes to endothelial cells. Naunyn-Schmiedebergs Arch Pharmacol 351 (Suppl): R130.

135 Stephens TD, Bunde CJW, Fillmore BJ (2000). Mechanism of action in thalidomide teratogenesis. Biochem Pharm,59; 12: 1489-1499.

136 Parman T, Wiley MJ, Wells PG (1999). Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med, 5: 582-585.

137 Koch H (1981). Die Arenoxid-Hypothese der Thalidomid-Wirkung. Überlegungen zum molekularen Wirkungsmechanismus des klassischen Teratogens. Sci Pharm 49: 67-99.

138 Langer S (1978). Colon-Nahttechnik: einreihige Naht. Langenbeck´s Arch Chir; 347: 601-604.

139 Jacobs G, Ulrich B (1981). Klammernahtgeräte an Magen und Dünndarm. Langenbeck´s Arch Chir; 355: 465-469.

140 Ellison GW (1989). Wound healing in the gastrointestinal tract. Semin Vet Med Surg; 4: 287-293.

141 Halsted WS (1887). Circular suture of the intestine - an experimental study. Am J Med Sci; 94: 436-461.

142 Junginger Th, Pichlmayr H. Nahtmaterialien und Nahttechniken in der Kolonchirurgie. In: Thiede A, Hamelmann H (Hrsg.) Moderne Nahtmaterialien und Nahttechniken in der Chirurgie. Berlin Heidelberg New York 1982: 288-295.

143 Brasken P, Lehto M, Renvall S (1990). Fibronectin, Laminin and collagen types I, III, IV and V in the healing rat colon anastomosis. Ann Chir Gynecol; 79: 65-71.


[Seite 136↓]

144 Grinnel F, Billingh R, Burgess L (1981). Distribution of fibronectin during wound healing in vivo. J Invest Dermatol; 76: 181-189.

145 Lehto M, Duance VC, Restall D (1985). Collagen and fibronectin in a healing skeletal muscle injury. J Bone Joint Surg (Brit); 67: 820-828.

146 Leder LD. Wundheilung und Fremdkörperreaktion. In Thiede A, Hamelmann H (Hrsg.) Moderne Nahtmaterialien und Nahttechniken in der Chirurgie. Berlin Heidelberg New York 1982: 226-228.

147 Kerscher P, Wünsch HP, Lehmann L, Eich J. Ist die alleinige Naht der Submukosa eine Alternative zu den bisherigen Nahttechniken ? In Thiede A, Hamelmann H (Hrsg.) Moderne Nahtmaterialien und Nahttechniken in der Chirurgie. Berlin Heidelberg New York 1982: 135-144.

148 Epstein EH, Munderloh NH (1975). Isolation and characterization of CNBr peptides of human [1(III)] 3 collagen and tissue distribution of [1(I)] 2 and [1(III)] 3 collagens. J Biol Chem; 25: 9304-9312.

149 Spjut HJ (1974). Microangiographic study of gastrointestinal lesions. Am J Roentgenol; 92: 1173-1187.

150 Abramovitz HB, Mc Alister WH (1969). A comparative study of small-bowel anastomoses by angiography and microangiography. Surgery; 66: 564-569.

151 Stelzner F (1982). Vorbeugung der intraperitonealen Nahtinsuffizienz (Dünn- und Dickdarm). Langenbeck´s Arch Chir; 358: 259-263.

152 Martens MFWC, Hendriks T (1991). Postoperative changes in collagen synthesis in intestinal anastomoses of the rat: differences between small and large bowel. Gut; 32: 1482-1487.

153 Wise L, Mc Alister W, Stein T, Schuck P (1975). Studies on the healing of anastomoses of small and large bowel. Surg Gynecol Obstet; 141: 190-194.

154 Nahai F, Lamb JM, Havican RG, Stone HH (1977). Factors involved in disruption of intestinal anastomoses. Am Surg; 43: 45-51.

155 Martens MFWC, Hendriks T (1989). Collagen synthesis in explants from rat intestine. Biochem Biophys Acta; 993: 252-258.

156 Pessa ME, Bland Kl, Copeland III EM (1987). Growth factors and determinants of wound repair. J Surg Res; 42: 207-217.


[Seite 137↓]

157 Ross R, Raines EW, Bowen-Pope DF (1986). The biology of plateled derived growth factor. Cell; 46: 155-169.

158 Barbul A, Caldwell M, Hunt TK (Eds). Growth factors and other aspects of wound healing: Biological and clinical implications. Progr in Clin and Biol Research, Vol 266, Alan Liss. New York 1988.

159 Brasken P, Renvall S, Sandberg M (1991). Expression of epidermal growth factor and epidermal growth factor receptor in healing colonic anastomoses in rats. Eur J Surg; 157: 607-611.

160 Kingsnorth AN, Vowles R, Nash JRG (1990). Epidermal growth factor increases tensile strengh in intestinal wounds in pigs. Brit J Surg; 77: 409-412.

161 Mateo RB, Reichner JS, Albina JE (1995). IL-6 activity in wounds. Am J Physiol; 35: R1840-1844.

162 Rappolee DA, Mark D, Banda MJ, Werb Z (1988). Wound macrophages express TGF-( and other growth factors in vivo. Analysis by m-RNA phanotyping. Science; 241: 708-712.

163 Brasken P (1991). Healing of experimental colonic anastomosis. Eur J Surg; 157 (Suppl 566): 1-51.

164 Jensen JA, Hunt TK, Scheuenstuhl H, Banda MJ (1986). Effect of lactate, pyruvate and pH on secretion of angiogenic and mitogenic factors by macrophages. Lab Invest; 54: 574-578.

165 Polverini PJ, Cotran RS, Gimbrone jr MA, Unanue ER (1977). Activated

166 Weinstat-Saslow D, Steeg PS (1994). Angiogenesis and colonization in the tumor metastatic process: Basic and applied advances. FASEB; 8: 401-407.

167 Fidler IJ (1991). Cancer metastasis. Br Med Bull; 47: 157-177.

168 Fidler IJ, Ellis LM (1994). The implication of angiogenesis for the biology and therapy of cancer metastasis. Cell; 79: 185-188.

169 De Vita VT, Hellman S, Rosenberg SA (1993). Cancer: Principles and Practice of Oncology. 134-149 (Lipincott, Philadelphia)

170 Crowley NJ, Seigler HF (1992). Relationship between disease-free-interval and survival in patients with recurrent melanoma. Arch Surg; 127: 1303-1308.

171 Demichelli R et al. (1994). Local recurrences following mastectomy: Support for the concept of tumor dormancy. J Natn Cancer Inst; 86: 45-48.

172 Meltzer A (1990). Dormancy and breast cancer. J Surg Oncol; 43: 181-188.


[Seite 138↓]

173 Holmgren L, O´Reilly MS, Folkman J (1995). Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Medicine; 1(2): 149-153.

174 Wheelock EF, Weinhold KJ, Levich J (1981). The tumor dormant state. Adv Cancer Res; 34: 107-140.

175 Woodruff M (1982). Interaction between cancer and host. The Walter Hubert Lecture. Brit J Cancer; 46: 313-322.

176 Noble RL, Hoover L (1975). A classification of transplantable tumors in NB rats controlled by estrogen from dormancy to autonomy. Cancer Res; 35: 2935-2941.

177 Bauer KH (1963), Das Krebsproblem. 2nd ed. Berlin, Göttingen, Heidelberg: Springer Verlag.

178 Mc Bride CM (1978). The surgeon as oncologist. South Med J; 71: 1331-1333.

179 Weiss L (1990). Metastatic inefficiency. Adv Cancer Res; 54: 159-211.

180 Kell MR, Winter DC, O`Sullivan GC et al. (2000). Biological behaviour and clinical implications of micrometastases. Br J Surg; 87: 1629-1639.

181 Hermanek P, Hutter P, Sobin LH, Wittekind C (1999). Classification of isolated tumor cells and micrometastasis. Cancer; 86: 2668-2673.

182 Willeke F, Sturm JW (2001). Minimal residual disease in soft tissue sarcomas. Semin Surg Oncol; 20: 294-303.

183 Shivers SC, Wang X, Li W et al. (1998). Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA; 280: 1410-1415.

184 Izbicki JR, Hosch SB, Passlick B et al (1996). Esophageal cancer: prognostic significance and therapeutic consequences of individual tumor cells in lymph nodes (abstract) Assoc. of Acad Departments of Surgery10° Annual Meeting: Bern.

185 Schlimok G, Funke I, Pantel K et al. (1991). Micrometastatic tumor cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance. Eur J Cancer; 27: 1461-1465.

186 Jauch KW, Heiss MM, Gruetzner KU et al. (1996). Prognostic significance of bone marrow micrometastasis in patients with gastric cancer. J Clin Oncol; 14: 1810-1817.

187 Lindemann F, Schlimock G, Dirschedl P et al. (1992). Prognostic significance of micrometastasic tumor cells in bone marrow of colorectal cancer patients. Lancet; 340 (8821): 685-689.


[Seite 139↓]

188 Weitz J, Kienle P, Magener A et al. (1998). Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin Cancer Res; 4: 343-348.

189 Rosenberg R, Hoos A, Mueller J, Nekarda H (2000). Impact of cytoceratin 20 and carcinoembryogenic antigen mRNA detection by RT-PCR in regional lymph nodes of patients with colorectal cancer. Brit J Cancer; 83: 1323-1329.

190 Fuatamura M, Takagi Y, Koumura H et al. (1998). Spread of colorectal cancer micrometastases in regional lymph nodes by reverse transcriptase polymerase chain reactions for carcinoembryogenic antigen and cytoceratin 20. J Surg Oncol; 68: 34-40.

191 Liefers GJ, Cleton-Janson AM, van de Velde JH et al. (1998). Micrometastases and survival in stage II colorectal cancer. N Engl J Med; 339: 223-228.

192 Weitz J, Herfarth C (2001). Surgical strategies and minimal residual disease detection. Semin Surg Oncol; 20: 329-333.

193 Hermanek P, Wittekind C (1994). Residual tumor (R) tumor classification and prognosis. Semin Surg Oncol; 10: 12-20.

194 Sobin LH, Wittekind C (1997). TNM-classification of malignant tumors. 5th edition, London: John Wiley & Sons, Inc.

195 Nishizaki T, Matsumata T, Kanematsu T (1990). Surgical manipulation of VX 2 carcinoma in the rabbit liver evokes enhancement of metastasis. J Surg Res ; 49: 92-97.

196 Barnes JP (1952). Physiologic resection of the right colon. Surg Gynecol Obstet; 94: 722-726.

197 Turnbull RB, Kyle K, Watson FR, Spratt J (1967). Cancer of the colon: the influence of the no-touch isolation technique on survival rates. Ann Surg; 166: 420-425.

198 Wiggers T, Jeekel J, Arends JW et al. (1994). No-touch isolation techniques in colon cancer: a controlled prospective trial. Brit J Surg; 75: 409-415.

199 Weitz J, Koch M, Kienle P, et al. (2000). Detection of hematogenic tumor cell determination in patients undergoing resection of liver metastases for colorectal cancer. Ann Surg; 232: 66-72.

200 Statistisches Bundesamt W. Statistisches Jahrbuch der Bundesrepublik Deutschland 1994. Wiesbaden: Wiesbadener Graphische Betriebe GMBH 1994.

201 Habilitationsarbeit PD Dr. med. W. Schwenk 1997. S. 5 folgende.

202 Eriksson T, Björkman S, Roth B, Björk B, Höglund P (1998). Hydroxylated Metabolites of Thalidomide: Formation In-vitro and In-vivo in Man. J Pharm Pharmacol; 50: 1409-1416.


[Seite 140↓]

203 Schumacher H, Smith RL, Williams RT (1965a). The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Brit J Pharmacol; 25: 324-337.

204 Schumacher H, Smith RL, Williams RT (1965b). The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Brit J Pharmacol; 25: 338-351.

205 Blaschke G, Hess HR, Lupke NP (1989). Synthese und teratogene Wirkung von N-Hydroxythalidomid. Arzneim Forsch; 39: 293-294.

206 Gordon GB, Spielberg SP, Blake DA, Balasubramanian V (1981). Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc Natl Acad Sci. USA; 78: 2545-2548.

207 Schumacher H, Blake D, Gillette JR (1968). Disposition of thalidomide in rabbits and rats. J Pharmacol Exp Ther; 160: 201-211.

208 Kotoh T, Dhar DK, Masunaga R et al (1999). Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice. Surgery; 125: 536-544.

209 Wiedemann HR (1961). Hinweis auf eine derzeitige Häufung hypo- und aplastischer Fehlbildung der Gliedmassen. Med Welt, 37: 1863.

210 Mc Bride WG (1961). Thalidomide and congenital abnormalities. Lancet; 2: 1358.

211 Lenz W (1962). Thalidomide and congenital abnormalities. Lancet; 1: 45.

212 Pfeifer RA, Kosenow W. (1962). Thalidomide and congenital abnormalities. Lancet; 1: 45-46.

213 Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP (1990). A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA; 87: 6624-6628.

214 Rastinejad F, Polverini PJ, Bouck NP (1989). Regulation of the activity of a new angiogenesis inhibitor by a cancer suppressor-gene. Cell; 56: 345-355.

215 Dameron KM, Volpert OV, Tainsky MA, Bouck NP (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science; 265: 1582-1584.

216 Moreira AL, Sampaio EP, Zmudzinas A et al. (1993). Thalidomide exerts ist inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med; 177: 1675-80.

217 Moreira AL, Tsenova-Berkova L, Wang J et al. (1997). Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis. Tubercle Lung Dis ; 78: 47-55.


[Seite 141↓]

218 Partida-Sanchez S, Favila-Castillo L, Pedraza-Sanchez S et al. (1998). IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment. Int Arch Allergy Immunol; 116: 60-66.

219 Rowland TL, Mc Hugh SM, Deighton J, et al. (1998). Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacol; 40: 11-20.

220 Rowland TL, Mc Hugh SM, Deighton J, et al. (1999). Selective down-regulation of T cell- and non-T-cell derived tumor necrosis factor alpha by thalidomide: comparison with dexamethasone. Immunol Lett; 68: 325-332.

221 Sampaio EP, Sarno EN, Galilly R et al. (1991). Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med; 173: 699-703.

222 Haslett P, Hempstead M, Seidman C et al. (1997). The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retrovir; 13: 1047-1054.

223 Shannon EJ, Sandoval F. (1995). Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin A, Staphylococcal enterotoxin A and purified protein derivate. Immunopharmacol; 31: 109-116.

224 Mc Hugh SM, Rifkin IR, Deighton J et al. (1995). The immunosuppressive drug thalidomide induces t-helper cell type 2 (Th 2) and concomitantly inhibits Th 1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol; 99: 160-167.

225 Moller DR, Wysocka M, Greenlee BM et al. (1997). Inhibition of IL-12 production by thalidomide. J Immunol; 159: 5157-5161.

226 Rowland TL, Mc Hugh SM, Deighton J, et al. (1998). Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacol; 40: 11-20.

227 Davies FE, Raje N, Hideshima T et al. (2001). Thalidomide and immunomodulatory derivates augment natural killer cell cytotoxicity in multiple myeloma. Blood; 98: 210-216.

228 Dimopoulos MA, Zomas A, Viniou NA et al. (2001). Treatment of Waldenström´s macroglobulinemia with thalidomide. J Clin Oncol; 19: 3596-3601.


[Seite 142↓]

229 Raza A, Myer P, Dutt D et al. (2001). Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood; 98: 958-965.

230 Fife K, Howard MR, Gracie F, Philipps RH, Bower M. (1998). Activity of thalidomide in AIDS-related Kaposi´s Sarcoma and correlation with HHV8 titre. Int J STD AIDS; 9: 751-755.

231 Little RF, Wyvill KM, Pluda JM et al. (2000). Activity of thalidomide in AIDS-related Kaposi´s Sarcoma. J Clin Oncol; 18: 2593-2602.

232 Eisen T, Boshoff C, Mak I et al. (2000). Continuous low-dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer; 82: 812-817.

233 Baidas SM, Winer EP, Fleming GF et al. (2000). Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol; 18: 2710-2717.

234 Metchnikoff E. " Zur Immunitätslehre". In 11. Deutscher Kongress f. Innere Medizin 1908, Leipzig: 282-289.

235 Tyrell J, Silberman H, Chandrasoma P, et al. (1989). Absorbable versus permanent mesh in abdominal operations. Surg Gynecol Obstet; 168(3): 227-232.

236 Hendriks JM, Hubens G, Wuyts FL, Vermeulen P, Hubens A, Eyskens E (1999). Br J Surg; 86(9): 1171-5.


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 3.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
05.02.2004